Recent developments for Hepion Pharmaceuticals include leadership changes, market listing transitions, partnership agreements, and corporate restructuring actions.

• Hepion Pharmaceuticals appointed Kaouthar Lbiati as interim CEO in June 2025 [N/A].
• The company initiated a transition to OTC Markets following a Nasdaq delisting notice in May 2025 [N/A].
• Hepion Pharmaceuticals entered into a binding letter of intent and partnership with New Day Diagnostics to commercialize CE-marked diagnostic tests in May 2025 [N/A].
• The company announced a 1-for-50 reverse stock split effective March 17, 2025 [N/A].
• Hepion Pharmaceuticals terminated a merger agreement with Pharma Two B Ltd in December 2024 [N/A].

Hepion Pharmaceuticals has taken steps to maintain its listing status through a reverse stock split and has engaged in partnerships to commercialize diagnostic products, indicating efforts to advance its business model. The company maintains strong liquidity ratios, which supports operational stability in the near term.

The company reported a net loss and negative earnings per share in the most recent quarter, indicating ongoing challenges in achieving profitability. The transition to OTC Markets following a Nasdaq delisting notice may reflect market or regulatory pressures. Termination of a merger agreement could indicate strategic or financial difficulties.

The company operates in the pharmaceutical sector with a focus on diagnostic test commercialization through partnerships, such as with New Day Diagnostics. Its moat may derive from proprietary technologies and regulatory approvals related to CE-marked diagnostic tests, though specific competitive advantages are not detailed in the available disclosures.

• Financial Performance Risk: The company reported a net loss of $1,248,237 and negative earnings per share for the quarter ended June 30, 2026, indicating ongoing unprofitability.
• Market Listing Risk: Hepion Pharmaceuticals initiated a transition to OTC Markets following a Nasdaq delisting notice, which may impact liquidity and investor perception.
• Strategic Execution Risk: The termination of a merger agreement with Pharma Two B Ltd suggests potential challenges in strategic partnerships or growth initiatives.

• Hepion Pharmaceuticals, Inc. is a publicly traded company with ticker HEPA.
• The company filed a 10-K annual report on March 11, 2026, and a 10-Q quarterly report on August 13, 2026, providing updated financial and operational information [S1][S2].
• As of June 30, 2026, Hepion Pharmaceuticals reported current assets of $1,927,442 and current liabilities of $492,759, resulting in a current ratio of 3.91 and a cash ratio of 28.26, indicating strong short-term liquidity [S2].
• The company had cash and cash equivalents of $13,922,972 as of December 31, 2019, per the latest available annual data [S1].
• For the quarter ended June 30, 2026, Hepion Pharmaceuticals reported a net loss of $1,248,237 and basic and diluted earnings per share of -$0.08 [S2].
• There have been no material changes to the risk factors disclosed in the 2025 Form 10-K as of the latest quarterly filing [S2].
• Recent corporate developments include the appointment of Kaouthar Lbiati as interim CEO in June 2025 [N/A].
• The company initiated a transition to OTC Markets following a Nasdaq delisting notice in May 2025 [N/A].
• Hepion Pharmaceuticals entered into a binding letter of intent and partnership with New Day Diagnostics to commercialize CE-marked diagnostic tests in May 2025 [N/A].
• The company announced a 1-for-50 reverse stock split effective March 17, 2025, to maintain Nasdaq listing [N/A].
• Hepion Pharmaceuticals terminated a merger agreement with Pharma Two B Ltd in December 2024 [N/A].